Jump to navigation Jump to search

| Verifiedfields = changed | verifiedrevid = 477241254 | IUPAC_name = (E)-3-{6-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-yl-
prop-1-enyl]pyridin-2-yl}prop-2-enoic acid | image =Acrivastine.png

| tradename = | = International Drug Names | MedlinePlus = a682619 | pregnancy_AU = | pregnancy_US = B | legal_AU = | legal_CA = | legal_UK = | legal_US = Rx-only | routes_of_administration = oral

| elimination_half-life = 1.5 hours | excretion = Renal

| CAS_number_Ref =  ☒N | CAS_number = 87848-99-5 | ATC_prefix = R06 | ATC_suffix = AX18 | PubChem = 5284514 | DrugBank_Ref =  ☑Y | ChemSpiderID_Ref =  ☑Y | ChemSpiderID = 4447574 | UNII_Ref =  ☑Y | UNII = A20F9XAI7W | KEGG_Ref =  ☑Y | KEGG = D02760 | ChEMBL_Ref =  ☑Y | ChEMBL = 1224 | ChEBI_Ref =  ☒N | ChEBI = 83168

| C=22 | H=24 | N=2 | O=2 | molecular_weight = 348.438 g/mol | smiles = O=C(O)\C=C\c3nc(\C(=C\CN1CCCC1)c2ccc(cc2)C)ccc3 | InChI = 1/C22H24N2O2/c1-17-7-9-18(10-8-17)20(13-16-24-14-2-3-15-24)21-6-4-5-19(23-21)11-12-22(25)26/h4-13H,2-3,14-16H2,1H3,(H,25,26)/b12-11+,20-13+ | InChIKey = PWACSDKDOHSSQD-IUTFFREVBW | StdInChI_Ref =  ☑Y | StdInChI = 1S/C22H24N2O2/c1-17-7-9-18(10-8-17)20(13-16-24-14-2-3-15-24)21-6-4-5-19(23-21)11-12-22(25)26/h4-13H,2-3,14-16H2,1H3,(H,25,26)/b12-11+,20-13+ | StdInChIKey_Ref =  ☑Y | StdInChIKey = PWACSDKDOHSSQD-IUTFFREVSA-N }}

WikiDoc Resources for Acrivastine


Most recent articles on Acrivastine

Most cited articles on Acrivastine

Review articles on Acrivastine

Articles on Acrivastine in N Eng J Med, Lancet, BMJ


Powerpoint slides on Acrivastine

Images of Acrivastine

Photos of Acrivastine

Podcasts & MP3s on Acrivastine

Videos on Acrivastine

Evidence Based Medicine

Cochrane Collaboration on Acrivastine

Bandolier on Acrivastine

TRIP on Acrivastine

Clinical Trials

Ongoing Trials on Acrivastine at Clinical

Trial results on Acrivastine

Clinical Trials on Acrivastine at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Acrivastine

NICE Guidance on Acrivastine


FDA on Acrivastine

CDC on Acrivastine


Books on Acrivastine


Acrivastine in the news

Be alerted to news on Acrivastine

News trends on Acrivastine


Blogs on Acrivastine


Definitions of Acrivastine

Patient Resources / Community

Patient resources on Acrivastine

Discussion groups on Acrivastine

Patient Handouts on Acrivastine

Directions to Hospitals Treating Acrivastine

Risk calculators and risk factors for Acrivastine

Healthcare Provider Resources

Symptoms of Acrivastine

Causes & Risk Factors for Acrivastine

Diagnostic studies for Acrivastine

Treatment of Acrivastine

Continuing Medical Education (CME)

CME Programs on Acrivastine


Acrivastine en Espanol

Acrivastine en Francais


Acrivastine in the Marketplace

Patents on Acrivastine

Experimental / Informatics

List of terms related to Acrivastine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Acrivastine is a medication used for the treatment of allergies and hay fever. It is a second-generation H1-receptor antagonist antihistamine (like its base molecule triprolidine) and works by blocking Histamine H1 receptors.

This non-sedating[verification needed] antihistamine is sold under the brand name Benadryl Allergy Relief in the United Kingdom by McNeil Laboratories, not to be confused with Benadryl Once a Day, which is cetirizine and is also sold by McNeil in the UK. It is available as an over-the-counter medication in the UK, also offered with pseudoephedrine under the Benadryl brand

In the U.S., acrivastine is the active ingredient in the Semprex brand. Semprex-D is also acrivastine-based, but contains a decongestant, pseudoephedrine. Semprex-D is marketed in the U.S. by Actient Pharmaceuticals.[1]

Comparisons with other popular antihistamines

Unlike cetirizine or loratadine, the standard dosage of which is one tablet every day, a single acrivastine tablet may be taken up to three times a day.[2] Not to be taken by over 65's, pregnant women or people with compromised liver or kidney function.

Pill Images

{{#ask: Page Name::Acrivastine |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }} {{#subobject:

 |Page Name=Acrivastine
 |Pill Name=SEMPREX_NDC_522440404.jpg
 |Drug Name=SEMPREX
 |Pill Imprint=404;SEMPREX;D
 |Pill Dosage=8 mg
 |Pill Color=Green|+sep=;
 |Pill Shape=Capsule
 |Pill Size (mm)=16
 |Pill Scoring=1
 |Pill Image=
 |Drug Author=Actient Pharmaceuticals, LLC



 |Page Name=Acrivastine
 |Pill Name=Semprex-D_NDC_530140404.jpg
 |Drug Name=Semprex-D
 |Pill Ingred=acrivastine[acrivastine];pseudoephedrine hydrochloride[pseudoephedrine]|+sep=;
 |Pill Imprint=404;SEMPREX-D
 |Pill Dosage=8 mg
 |Pill Color=Green;White|+sep=;
 |Pill Shape=Capsule
 |Pill Size (mm)=16
 |Pill Scoring=1
 |Pill Image=
 |Drug Author=UCB, Inc.



  1. SEMPREX-D - acrivastine and pseudoephedrine hydrochloride capsule U.S. National Library of Medicine, National Institutes of Health, May 2008
  2. "Benadryl Allergy Relief". electronic Medicines Compendium (eMC). 2014. Retrieved 4 July 2014.